25 results
8-K
EX-99.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
Therapeutics into its next phase of growth and innovation, and most importantly, making a difference in the lives of patients suffering from autoimmune … and was promoted to CEO in October 2018. Prior to Synlogic, Dr. Brennan served as Vice President and Head of the Rare Disease Innovation Unit at Biogen, Inc
8-K
EX-99.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
or licensed from third parties. We also rely on know-how relating to our proprietary technology, product candidates and continuing innovation … Care and Education Reconciliation Act signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009
DEFA14A
ELYM
Eliem Therapeutics Inc
12 Jun 24
Additional proxy soliciting materials
4:42pm
”) from October 2018 to March 2024. Prior to joining Synlogic, Dr. Brennan served as Vice President and Head of the Rare Disease Innovation Unit
8-K
ELYM
Eliem Therapeutics Inc
12 Jun 24
Departure of Directors or Certain Officers
4:41pm
to joining Synlogic, Dr. Brennan served as Vice President and Head of the Rare Disease Innovation Unit at Biogen Inc. where her responsibilities
DEFM14A
ELYM
Eliem Therapeutics Inc
4 Jun 24
Proxy related to merger
8:00am
third parties. Tenet also relies on know-how relating to its proprietary technology, product candidates and continuing innovation to develop, strengthen … Reconciliation Act signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”), which
PREM14A
9wah9fk
17 May 24
Preliminary proxy related to merger
4:36pm
DEFA14A
c9qf716
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-10.5
u4v7erpi9x6e o0cv
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.3
2rt9aitpknx88 zk
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.4
ivqo2rj71oc
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
10-K
vte1p614v6d7
7 Mar 22
Annual report
4:03pm
424B4
otf5s
11 Aug 21
Prospectus supplement with pricing info
5:05pm